Cirrhosis Clinical Trials
Here are the 6 most popular medical studies for cirrhosis
Procedure
TIPS Procedure for Liver Cirrhosis and Muscle Loss
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
Amino Acid Supplement
Leucine Enriched Amino Acids for Liver Cirrhosis
This trial is testing whether leucine will help increase muscle mass in people with cirrhosis, by looking at the response to leucine in cirrhotic patients compared to a control group. They will measure this by looking at the rate of protein synthesis in muscle, and how this changes in response to leucine.
Caspase Inhibitor
Emricasan for Cirrhosis
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.
Popular filter options for cirrhosis trials
Portal Hypertension Clinical Trials
View 10 Portal Hypertension medical studies.
Cholates Compound for Liver Disease
This trial aims to improve the evaluation of patients with advanced liver disease. Currently, the assessment is limited to imaging, liver function tests, and liver biopsy. However, with advancements in treatments and liver transplantation
Procedure
BI 685509 + Empagliflozin for Portal Hypertension
This trial is for adults with liver cirrhosis caused by hepatitis B, hepatitis C, or nonalcoholic steatohepatitis. The study is testing whether BI 685509, taken alone or with empagliflozin, helps people with this condition by checking the pressure in a liver vein.
BI 685509 for Portal Hypertension
This trial is testing whether a medicine called BI 685509 can help people with liver cirrhosis and high blood pressure in the portal vein. People are randomly put into 3 groups, taking BI 685509 or placebo tablets twice a day for 8 months. The study measures the change in blood pressure to see if the treatment is effective.
Phase 3 Cirrhosis Clinical Trials
View 52 phase 3 cirrhosis medical studies.
Statin
Simvastatin for Liver Cirrhosis
This trial will test whether simvastatin can lower the risk of hepatic decompensation in people with compensated cirrhosis. It will also explore how changes in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.
Cirrhosis Clinical Trials With No Placebo
View 52 cirrhosis medical studies that do not have a placebo group.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Cholates Compound for Liver Disease
This trial aims to improve the evaluation of patients with advanced liver disease. Currently, the assessment is limited to imaging, liver function tests, and liver biopsy. However, with advancements in treatments and liver transplantation
View More Cirrhosis Trials
See another 26 medical studies focused on cirrhosis.
Frequently Asked Questions
Introduction to cirrhosis
What are the top hospitals conducting cirrhosis research?
When it comes to advancing the understanding and treatment of cirrhosis, several top hospitals are leading the way with their extensive clinical trial programs. In Pasadena, California Liver Research Institute is making significant strides with five ongoing trials focused specifically on cirrhosis. Since their first recorded cirrhosis trial in 2015, they have shown a commitment to exploring new approaches for this complex condition. Similarly, the University of California San Francisco in San Francisco has been at the forefront of cirrhosis research since 2013 when they initiated their first trial. Currently conducting four active trials, they continue to contribute valuable knowledge to the field.
Meanwhile, across the country in Richmond, Virginia, Hunter Holmes McGuire VA Medical Center is also dedicated to addressing cirrhosis through innovative clinical trials. With a total of 19 completed studies and four ongoing ones aimed at improving outcomes for patients with this liver disease since their initial trial in 2011; they have demonstrated a long-standing commitment to advancing medical knowledge surrounding this condition.
In Baltimore's Mercy Medical Center where twelve past investigations already took place after initially starting from as recent as almost ten years back until 2012; it currently holds an impressive record of managing such cases by having actively running additional four more tests presently underway Meanwhile at Mayo Clinic located Rochester; esteemed institution that can trace its involvement in studying Cirrhosis dating all way back till1997.While there are currently four active clinical trials happening here now,the Mayo Clinic’s cumulative contribution consists of twenty-three previous studies conducted over time.
These renowned institutions demonstrate unwavering dedication not only towards treating those affected by cirrhosis but also furthering our understanding about this complex liver disease impacting millions globally each year.Through these collaborative efforts and pioneering research initiatives we move closer toward improved management strategies enhanced quality-of-life options,and ultimately greater hope for individuals living with or facing potential risk factors associated within Mild-to-severe stages associated Cirrhotic conditions.
Which are the best cities for cirrhosis clinical trials?
Richmond, Virginia; Houston and Dallas, Texas; Seattle, Washington; and New york, New York are among the best cities for cirrhosis clinical trials. Richmond leads with 20 active trials focused on promising treatments such as Rifaximin SSD, belapectin, and Health IT +/- Scheduled Follow Up. Houston and Dallas follow closely behind with 17 ongoing studies examining interventions like Emricasan (5 mg) and LPCN 1148. Seattle and New York also contribute to advancements in cirrhosis research with their respective portfolios of 16 active trials investigating innovative approaches like Semaglutide (SEMA) and Survey-based Patient/Clinician Jumpstart. These cities offer individuals suffering from cirrhosis access to cutting-edge clinical trials that may lead to improved treatment options.
Which are the top treatments for cirrhosis being explored in clinical trials?
Clinical trials exploring potential treatments for cirrhosis have identified two promising interventions. The Jumpstart Guide, introduced in 2023, is currently part of one active trial and represents a novel approach to tackling this condition. Similarly, the Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation procedure, first listed in 2022, has also garnered attention with one ongoing clinical trial dedicated to studying its effectiveness in cirrhosis treatment. These advancements offer hope for patients living with this challenging liver disease and may pave the way for improved outcomes in the future.
What are the most recent clinical trials for cirrhosis?
Exciting developments are unfolding in the field of cirrhosis treatment, with recent clinical trials offering promising avenues for patients. One noteworthy trial involves Seladelpar 10 mg, which has entered Phase 3 and shows potential for treating cirrhosis. Additionally, a Phase 2 study called Active demonstrates encouraging outcomes for this condition. Another trial, known as Arm 1, is progressing through both Phase 2 and Phase 3 stages and holds promise as well. Furthermore, a Phase 3 trial examines the benefits of adding lactulose to enhanced usual care in cirrhosis treatment. Lastly, Danazol Pill has shown promise in its early stages (Phase 2) as a potential therapy option for individuals affected by cirrhosis. These breakthroughs fuel optimism within the medical community as we strive towards improving outcomes for those battling this challenging disease.
What cirrhosis clinical trials were recently completed?
Several significant clinical trials in the field of cirrhosis have recently concluded, bringing hope for improved treatments. Stanford University completed a trial investigating Empagliflozin 10 MG in November 2021, while the University of Michigan explored the potential benefits of Lactulose during a trial that also finished that month. Georgetown University wrapped up their study on Proglumide in March 2021. These recent advancements highlight ongoing efforts to combat cirrhosis and provide valuable insights into potential therapeutic options for patients with this condition.